Biocytogen will be attending the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, taking place from May 4–8, 2025, in Salt Lake City, Utah. During the conference, Biocytogen will present a poster highlighting the latest advancements in the development of innovative therapeutic strategies for Thyroid Eye Disease (TED).
Poster Presentation Details:
Poster #4304: BCG009, a fully human anti-IGF-1R antibody as a second-generation therapeutics for the indication of Thyroid Eye Disease (TED)
Session Topic: Thyroid and Neuro Ophthalmology
Presentation Time: May 7th, 2025 | 10:15 AM – 12:00 PM
Location: Salt Palace Convention Center, Halls A–E
BCG009 is a second-generation fully human anti-IGF-1R antibody developed using Biocytogen’s proprietary RenMab® platform. In vitro studies have demonstrated its potent signaling blockade activity. Additionally, BCG009 effectively inhibits hyaluronic acid (HA) secretion in orbital fibroblasts derived from TED patients. The antibody also exhibits extended pharmacokinetics (PK) and favorable solubility suitable for high-concentration formulations, highlighting its strong development potential. Pharmacokinetic and safety data in non-human primates will also be shared at the conference.
This project is a collaborative effort between Biocytogen and Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., launched in 2022. The partnership combines Biocytogen’s expertise in identifying high-quality antibody candidates through its initiative, The Global Headstream of New Drugs with Cutting-Edge Antibody Assets, with Chia Tai Tianqing’s strong capabilities in clinical development, industrialization, and commercialization. Together, the two companies aim to accelerate the research and development of antibody-based therapeutics and deliver safer, more effective treatment options for patients worldwide.
Dr. Frank An, Vice President of Biocytogen’s Institute of Biologics, Dr. Chaoshe Guo, Vice President and Global Head of Business Development, along with the BD & Licensing team, will be presenting the poster at ARVO 2025. We warmly invite professionals in the fields of ophthalmology and immunological diseases to visit our booth and connect with us.
To schedule a one-on-one meeting, please contact us at: BD-Licensing@biocytogen.com
